Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon free therapy with direct acting antivirals for HCV.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2013

Asselah Tarik, Marcellin Patrick

Abstract excerpt

The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response (SVR) rates with oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Structure

Share to Polyethylene Glycols

Share to Ribavirin

Share to Serine Proteinase Inhibitors

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 23286852
DOI: 10.1111/liv.12076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon free therapy with direct acting antivirals for HCV.PMID 23286852Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

Future perspectives: towards interferon-free regimens for HCV.Semantic proximity Read ↗

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.Semantic proximity Read ↗

Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.Semantic proximity Read ↗

Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.Semantic proximity Read ↗

Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection.Semantic proximity Read ↗

Interferon-free regimens for hepatitis C: combine and conquer.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.